恒瑞医药(01276)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01276 恒瑞医药

已收盘 08-20 16:09:09

49.660

-5.290

-9.63%

最高53.000	最低48.800	成交量2,823万
今开52.800	昨收54.950	日振幅7.64%
总市值3,296亿	流通市值128.12亿	总股本66.37亿
成交额14.31亿	换手率10.94%	流通股本2.58亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"恒瑞医药","latestPrice":49.66,"timestamp":1787213349002,"preClose":54.95,"halted":0,"volume":28227691,"delay":0,"changeRate":-0.09626933575978174,"floatShares":258000000,"shares":6637000000,"eps":1.375813720031057,"marketStatus":"已收盘","change":-5.29,"latestTime":"08-20 16:09:09","open":52.8,"high":53,"low":48.8,"amount":1430671791,"amplitude":0.076433,"askPrice":49.7,"askSize":156000,"bidPrice":49.66,"bidSize":13800,"shortable":3,"etf":0,"ttmEps":1.4232886209227726,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787275800000},"marketStatusCode":5,"adr":0,"listingDate":1747929600000,"exchange":"SEHK","adjPreClose":54.95,"dividendRate":0.004684,"openAndCloseTimeList":[[1787189400000,1787198400000],[1787202000000,1787212800000]],"volumeRatio":5.037742,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"恒瑞医药","latestPrice":49.5,"timestamp":1787209200000,"preClose":52.66,"halted":0,"volume":238741600,"delay":0,"premium":"-13.96"}},"requestUrl":"/m/hq/s/01276/tweets","defaultTab":"tweets","newsList":[{"id":"1143598499","title":"恒瑞医药自主研发1类创新药利康帕泛富马酸（HRS-5965）胶囊获国家药监局批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1143598499","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1143598499?lang=zh_cn&edition=full","pubTime":"2026-08-20 18:35","pubTimestamp":1787222114,"startTime":"0","endTime":"0","summary":"恒瑞医药宣布，其自主研发的1类创新药利康帕泛富马酸胶囊已正式获得国家药品监督管理局批准，准许上市销售。这一里程碑式的进展，标志着公司在创新药研发领域再度取得重大突破。据悉，该药物作为全新一代治疗产品，其获批上市有望为相关疾病患者提供全新的治疗选择。值得注意的是，利康帕泛富马酸胶囊从临床前研究到最终获批，历经了严格的科学验证与审评流程，其安全性、有效性及质量可控性均获得了监管部门的充分认可。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","LU1328615791.USD","LU1997245094.SGD","LU1820825898.SGD","BK0060","LU2580892789.USD","LU2097828631.EUR","LU2097828805.USD","BK0188","LU2097828474.EUR","LU0405327494.USD","LU1997244956.HKD","LU1023057109.AUD","LU2097828714.EUR","LU0359201612.USD","LU2495084118.USD","600276","LU1655091616.SGD","LU2289578879.USD","LU1997245177.USD","LU2148510915.USD","LU2580892862.HKD","LU2328871848.SGD","LU2488822045.USD","LU0359201885.HKD","BK0028","LU2097828557.USD","LU1064130708.USD","LU1064131003.USD","LU1255011170.USD","LU1969619763.USD","LU2543165471.USD","01276","LU0405327148.USD","BK0012","LU1580142542.USD","LU1781817850.SGD","BK0183","LU1146622755.USD","LU0359202008.SGD","BK1191","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173056686","title":"恒瑞医药获批开展HRS-3095片ITP及AIHA适应症临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1173056686","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1173056686?lang=zh_cn&edition=full","pubTime":"2026-08-20 18:32","pubTimestamp":1787221966,"startTime":"0","endTime":"0","summary":"2026年8月20日，恒瑞医药公告称，其子公司成都盛迪医药有限公司已收到国家药品监督管理局核准签发的HRS-3095片《药物临床试验批准通知书》，同意该药物用于原发免疫性血小板减少症和自身免疫性溶血性贫血的临床试验。此次临床试验申请受理号为CXHL2600653、CXHL2600654、CXHL2600655及CXHL2600656，受理日期为2026年6月3日。恒瑞医药表示将按监管要求推进项目进展，并及时披露后续信息。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660837902","title":"恒瑞医药(01276) ：SHR-7012 注射液拟用于治疗皮肤型红斑狼疮获批开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2660837902","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660837902?lang=zh_cn&edition=full","pubTime":"2026-08-20 18:22","pubTimestamp":1787221372,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)公布，近日，公司子公司广东恒瑞医药有限公司收到国家药品监督管理局核准签发关于 SHR-7012 注射液的《药物临床试验批准通知书》，将于近期开展临床试验。SHR-7012 注射液是公司自主研发的创新型药物，拟用于治疗皮肤型红斑狼疮。经查询，国内外目前暂无同靶点药物获批上市。截至目前，SHR-7012 注射液相关项目累计研发投入约 2,550 万元(未经审计)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1482720.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2097828631.EUR","LU1023057109.AUD","LU1655091616.SGD","LU2289578879.USD","600276","01276","LU1997245177.USD","LU2488822045.USD","MDTX","BK0196","LU1997244956.HKD","BK0183","BK0028","BK0012","LU2543165471.USD","PSYK","LU2580892789.USD","LU1969619763.USD","LU1146622755.USD","LU1781817850.SGD","LU0405327148.USD","BK0188","LU2097828474.EUR","BK0239","LU1064131003.USD","IBBJ","BK1191","LU0359202008.SGD","LU1997245094.SGD","LU1255011170.USD","LU1328615791.USD","LU2148510915.USD","LU0405327494.USD","LU0359201612.USD","LU2328871848.SGD","IBBQ","BK0060","LU2580892862.HKD","LU1580142542.USD","LU2097828557.USD","LU1820825898.SGD","BMED","LU2097828805.USD","LU2495084118.USD","LU0359201885.HKD","LU2097828714.EUR","LU1064130708.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161547637","title":"恒瑞医药获批开展SHR-7012注射液临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1161547637","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1161547637?lang=zh_cn&edition=full","pubTime":"2026-08-20 18:20","pubTimestamp":1787221230,"startTime":"0","endTime":"0","summary":"2026年8月20日，江蘇恒瑞醫藥股份有限公司公告称，其子公司广东恒瑞医药有限公司已收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，同意对创新药物SHR-7012注射液开展临床试验。公告显示，SHR-7012拟用于治疗皮肤型红斑狼疮，受理号为CXSL2600557。SHR-7012为公司自主研发，目前国内外暂无同靶点药物获批上市。恒瑞医药提示，药品从临床试验至最终上市尚需经过多环节审批，存在不确定性风险。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161718052","title":"恒瑞医药(01276)获批开展SHR-8203注射液晚期实体瘤临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1161718052","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1161718052?lang=zh_cn&edition=full","pubTime":"2026-08-20 18:15","pubTimestamp":1787220936,"startTime":"0","endTime":"0","summary":"2026年8月20日，恒瑞医药(01276)公告称，其子公司北京盛迪医药有限公司已收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，同意在晚期实体瘤患者中开展SHR-8203注射液的单药临床试验。批准对应受理号为CXSL2600576。\nSHR-8203注射液为公司自主研发的创新型抗肿瘤药物，拟用于治疗晚期实体瘤。截至目前，该项目累计研发投入约2,040万元（未经审计）。经公司查询，国内外尚无同类药物上市。\n公司提示，药物上市仍需完成临床试验并通过国家药监局后续审评审批，研发及上市周期存在不确定性。公司将按相关法规推进项目进展，并及时披露后续信息。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660283172","title":"恒瑞医药(01276.HK)：SHR-8203 注射液获药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2660283172","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660283172?lang=zh_cn&edition=full","pubTime":"2026-08-20 18:15","pubTimestamp":1787220934,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","LU2543165471.USD","LU0359201885.HKD","LU1023057109.AUD","LU0359202008.SGD","LU0359201612.USD","01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660283161","title":"恒瑞医药富马酸立康可泮胶囊获药品注册批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2660283161","media":"北京商报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660283161?lang=zh_cn&edition=full","pubTime":"2026-08-20 17:59","pubTimestamp":1787219960,"startTime":"0","endTime":"0","summary":"8月20日，恒瑞医药发布公告称，公司子公司成都盛迪医药有限公司近日收到国家药品监督管理局的通知，批准公司自主研发的1类新药富马酸立康可泮（HRS-5965）胶囊上市。根据公告，富马酸立康可泮胶囊是一种补体因子B抑制剂，作为靶向补体旁路途径的近端补体抑制，其通过抑制旁路途径的异常激活与补体扩增循环，从机制层面同时抑制血管内溶血和血管外溶血，提升血红蛋白水平。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608203847895762.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608203847895762.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0028","LU1997245177.USD","LU0359201612.USD","LU0359201885.HKD","LU2097828474.EUR","LU2580892862.HKD","LU1655091616.SGD","LU2328871848.SGD","LU2097828557.USD","BK0183","LU1820825898.SGD","LU1064130708.USD","LU2580892789.USD","LU0359202008.SGD","LU2495084118.USD","LU2097828631.EUR","LU0405327148.USD","LU2488822045.USD","BK1191","LU1580142542.USD","BK0060","LU2543165471.USD","LU1146622755.USD","LU1255011170.USD","LU2097828714.EUR","BK0196","LU2289578879.USD","LU1997244956.HKD","BK0012","600276","01276","LU1023057109.AUD","BK0188","LU1969619763.USD","LU2148510915.USD","LU1328615791.USD","LU2097828805.USD","LU1781817850.SGD","BK0239","LU1064131003.USD","LU1997245094.SGD","LU0405327494.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660407083","title":"恒瑞医药：子公司3款药物获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2660407083","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660407083?lang=zh_cn&edition=full","pubTime":"2026-08-20 17:02","pubTimestamp":1787216520,"startTime":"0","endTime":"0","summary":"8月20日，恒瑞医药（600276/01276）发布公告，公司子公司北京盛迪、广东恒瑞及成都盛迪分别收到国家药监局核准签发的《药物临床试验批准通知书》，涉及SHR-8203注射液、SHR-7012注射液及HRS-3095片三款药物，均将于近期开展临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608203847831616.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608203847831616.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["600276","LU1023057109.AUD","LU2488822045.USD","LU1580142542.USD","LU1781817850.SGD","LU0359201885.HKD","BK0060","LU1255011170.USD","LU2580892789.USD","BK0196","LU2580892862.HKD","LU1655091616.SGD","LU1997245177.USD","LU2097828714.EUR","LU2148510915.USD","BK0183","LU2289578879.USD","LU0405327494.USD","01276","LU1969619763.USD","LU2097828631.EUR","LU1064130708.USD","LU1064131003.USD","LU2543165471.USD","LU1328615791.USD","LU2097828805.USD","LU2328871848.SGD","BK0012","LU2097828474.EUR","BK1191","LU1146622755.USD","BK0188","LU2097828557.USD","BK0239","LU0359201612.USD","LU1820825898.SGD","LU1997245094.SGD","LU0359202008.SGD","LU1997244956.HKD","LU0405327148.USD","BK0028","LU2495084118.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660402211","title":"恒瑞医药：HRS-3095片获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2660402211","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660402211?lang=zh_cn&edition=full","pubTime":"2026-08-20 16:41","pubTimestamp":1787215260,"startTime":"0","endTime":"0","summary":"南财智讯8月20日电，恒瑞医药公告，HRS-3095片收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，同意开展原发免疫性血小板减少症（ITP）和自身免疫性溶血性贫血（AIHA）的临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608203847797826.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608203847797826.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","LU1328615791.USD","LU1997245094.SGD","LU1820825898.SGD","BK0060","LU2580892789.USD","LU2097828631.EUR","LU2097828805.USD","BK0188","LU2097828474.EUR","LU0405327494.USD","LU1997244956.HKD","LU1023057109.AUD","LU2097828714.EUR","MDTX","LU0359201612.USD","LU2495084118.USD","600276","LU1655091616.SGD","LU2289578879.USD","LU1997245177.USD","LU2148510915.USD","LU2580892862.HKD","LU2328871848.SGD","LU2488822045.USD","LU0359201885.HKD","PSYK","BK0028","IBBQ","LU2097828557.USD","LU1064130708.USD","IBBJ","LU1064131003.USD","LU1255011170.USD","LU1969619763.USD","01276","LU2543165471.USD","LU0405327148.USD","BK0012","LU1580142542.USD","LU1781817850.SGD","BK0183","LU1146622755.USD","BMED","LU0359202008.SGD","BK1191","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660402861","title":"为什么说恒瑞医药未来的增长依然具有高确定性","url":"https://stock-news.laohu8.com/highlight/detail?id=2660402861","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660402861?lang=zh_cn&edition=full","pubTime":"2026-08-20 16:18","pubTimestamp":1787213921,"startTime":"0","endTime":"0","summary":"半年报显示，恒瑞医药2026年上半年营收154.56亿元，同比下降1.94%；归母净利润44.65亿元，同比增长0.34%。三条曲线层层递进，恒瑞医药的未来增长逻辑依然具有高确定性。随着创新药占比的不断提升，恒瑞医药的增长引擎的切换已经完成。截至目前，恒瑞已在中国获批27款1类创新药、6款2类新药。因此走向全球对于恒瑞而言正在从偶发性事件变成常态化业务，从而不断拔高公司未来成长的天花板。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026082000027713.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2495084118.USD","LU2543165471.USD","01276","LU2580892789.USD","LU1023057109.AUD","BK0012","LU0405327494.USD","LU1997245094.SGD","LU0359201885.HKD","LU2097828631.EUR","BK0028","LU2328871848.SGD","LU1969619763.USD","LU2488822045.USD","LU1655091616.SGD","LU2148510915.USD","BK0060","LU1781817850.SGD","LU1997244956.HKD","BK0188","LU2097828805.USD","LU2097828557.USD","LU1328615791.USD","LU2580892862.HKD","BK0239","BK0196","LU0359201612.USD","LU2289578879.USD","LU1580142542.USD","LU0359202008.SGD","BK1191","LU1997245177.USD","LU1146622755.USD","LU2097828474.EUR","LU1820825898.SGD","LU1064131003.USD","LU1064130708.USD","LU2097828714.EUR","600276","LU1255011170.USD","BK0183","LU0405327148.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660477226","title":"恒瑞医药上半年营收155亿：扣非后净利37亿 同比降12.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660477226","media":"雷递网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660477226?lang=zh_cn&edition=full","pubTime":"2026-08-20 10:35","pubTimestamp":1787193354,"startTime":"0","endTime":"0","summary":"江苏恒瑞医药股份有限公司（公司代码：600276 公司简称：恒瑞医药）日前发布2026年上半年的财报。财报显示，恒瑞医药2026年上半年营收为154.56亿，较上年同期的157.6亿下降1.94%。","market":"sh","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260820/6392281893802290605569023.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260820/6392281893802290605569023.jpeg"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n34754/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["01276","600276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660472163","title":"恒瑞医药半年报：赚了44.65亿元，创新药撑起六成营收","url":"https://stock-news.laohu8.com/highlight/detail?id=2660472163","media":"新京报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660472163?lang=zh_cn&edition=full","pubTime":"2026-08-20 09:34","pubTimestamp":1787189640,"startTime":"0","endTime":"0","summary":"8月19日，恒瑞医药发布2026年中报。报告期内，公司实现营业收入154.56亿元，同比减少1.94%；归母净利润44.65亿元，同比增加0.34%。2026年上半年，公司创新药销售收入88.09亿元，同比增长16.38%，占药品销售收入的比重进一步提升至63.16%。创新药销售收入中，抗肿瘤产品收入62.65亿元，同比增长2.58%，占创新药销售收入的71.11%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608203847287817.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608203847287817.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["600276","LNGR","01276","06978","159992","MEDX","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121731006","title":"异动解读｜恒瑞医药盘中下跌8.55%，中报营收下滑扣非净利大降","url":"https://stock-news.laohu8.com/highlight/detail?id=1121731006","media":"行情直击","labels":[],"top":1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121731006?lang=zh_cn&edition=full","pubTime":"2026-08-20 09:33","pubTimestamp":1787189580,"startTime":"0","endTime":"0","summary":"8月20日，恒瑞医药盘中下跌8.55%，报49.5港元，成交额7873.85万港元。消息面上，公司8月19日晚间发布上半年财报，营业收入154.56亿元，同比下降1.94%；归母净利润44.65亿元，同比仅增0.34%；扣非归母净利润37.30亿元，同比大幅下滑12.71%；经营活动现金流净额19.87亿元，同比骤降53.8%。虽然创新药销售收入88.09亿元同比增长16.4%，但仿制药收入51.39亿元同比下滑16.07%，对外许可收入14.22亿元同比降28.6%，主业盈利质量明显承压。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"恒瑞医药盘中下跌8.55%，中报营收下滑扣非净利大降","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142006575","title":"恒瑞医药（01276）宣布董事会秘书变更 刘笑含辞任田飞接任","url":"https://stock-news.laohu8.com/highlight/detail?id=1142006575","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142006575?lang=zh_cn&edition=full","pubTime":"2026-08-19 22:21","pubTimestamp":1787149261,"startTime":"0","endTime":"0","summary":"2026年8月19日，恒瑞医药发布公告称，董事会秘书兼联席公司秘书刘笑含因个人原因提出辞职，辞职报告自送达董事会之日起生效。刘笑含原任期至2029年4月15日，其离任后不再在公司及控股子公司担任任何职务，亦不存在未履行完毕的公开承诺。公司确认其离任不会对正常运营造成影响，另一名联席公司秘书梁颖娴将继续履行公司秘书职责。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183935914","title":"恒瑞医药完成10.04亿元股份回购 1,659.10万股将用于员工持股计划","url":"https://stock-news.laohu8.com/highlight/detail?id=1183935914","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1183935914?lang=zh_cn&edition=full","pubTime":"2026-08-19 22:20","pubTimestamp":1787149257,"startTime":"0","endTime":"0","summary":"2026年8月19日，江苏恒瑞医药股份有限公司公告称，其于2025年8月20日至2026年8月19日期间实施的A股股份回购已完成。本次回购共计购回16,591,040股，占公司总股本的0.25%。公司表示，已回购的1,659.10万股将全部用于实施A股员工持股计划，并承诺在回购完成后36个月内完成授予或转让；逾期未使用的股份将依法注销。回购完成后，公司总股本保持6,637,199,874股不变，其中回购专用证券账户股份余额为11,431,250股，占总股本的0.17%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660299334","title":"恒瑞医药(01276)：田飞获聘任为董事会秘书","url":"https://stock-news.laohu8.com/highlight/detail?id=2660299334","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660299334?lang=zh_cn&edition=full","pubTime":"2026-08-19 22:20","pubTimestamp":1787149210,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)发布公告，经公司董事长提名，并经公司董事会提名委员会审查通过，公司于2026年8月19日召开的第十届董事会第四次会议审议通过了《关于变更公司董事会秘书的议案》，同意聘任田飞先生为董事会秘书。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1482279.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0359202008.SGD","LU2488822045.USD","BK0183","BK0060","BK1191","LU1820825898.SGD","LU1997244956.HKD","LU2097828714.EUR","LU2580892789.USD","LU2148510915.USD","LU1655091616.SGD","LU1781817850.SGD","LU0405327494.USD","LU1146622755.USD","01276","LU1997245094.SGD","LU2495084118.USD","LU2289578879.USD","BK0239","LU2097828805.USD","LU2580892862.HKD","LU0405327148.USD","LU1580142542.USD","BK0012","BK0028","BK0196","LU1255011170.USD","600276","LU0359201612.USD","BK0188","LU1064131003.USD","LU0359201885.HKD","LU2097828631.EUR","LU1328615791.USD","LU2097828474.EUR","LU2543165471.USD","LU1023057109.AUD","LU1064130708.USD","LU1997245177.USD","LU1969619763.USD","LU2097828557.USD","LU2328871848.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660429685","title":"恒瑞医药(01276.HK)拟回购10亿-20亿元的A股股份用于 A 股员工持股计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2660429685","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660429685?lang=zh_cn&edition=full","pubTime":"2026-08-19 22:18","pubTimestamp":1787149098,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["07233","LU1023057109.AUD","83130","01276","03188","LU0359202008.SGD","LU0359201885.HKD","02827","02846","03130","BK1147","LU0359201612.USD","LU2543165471.USD","82846","BK1191","83188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153343548","title":"恒瑞医药(01276)职工代表大会通过2026年A股员工持股计划草案","url":"https://stock-news.laohu8.com/highlight/detail?id=1153343548","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153343548?lang=zh_cn&edition=full","pubTime":"2026-08-19 22:17","pubTimestamp":1787149025,"startTime":"0","endTime":"0","summary":"2026年8月19日，恒瑞医药股份有限公司公告称，公司第六届职工代表大会第五次会议已于2026年8月18日以现场结合通讯方式召开，并审议通过《关于<江苏恒瑞医药股份有限公司2026年A股员工持股计划（草案）>及其摘要的议案》。\\n\\n公司强调，在员工持股计划实施前已充分征求员工意见，公告中确认不存在损害公司及全体股东利益或强制员工参与的情况。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112295035","title":"恒瑞医药公布最高20亿元A股回购方案 期限不超12个月","url":"https://stock-news.laohu8.com/highlight/detail?id=1112295035","media":"公告速递","labels":["shareholding","buyback","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1112295035?lang=zh_cn&edition=full","pubTime":"2026-08-19 22:16","pubTimestamp":1787148980,"startTime":"0","endTime":"0","summary":"江苏恒瑞医药股份有限公司8月19日发布公告称，公司董事会当日审议通过以集中竞价交易方式回购A股股份的方案，计划使用自有资金不低于10亿元、且不超过20亿元回购公司A股。恒瑞医药同时提示风险：若股票价格持续高于回购价格上限、资金未能及时到位、公司经营状况发生重大变化，或员工持股计划未能实施等，均可能导致回购方案变更或终止。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1172045194","title":"恒瑞医药（01276）公布2026年A股员工持股计划关键条款","url":"https://stock-news.laohu8.com/highlight/detail?id=1172045194","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172045194?lang=zh_cn&edition=full","pubTime":"2026-08-19 22:15","pubTimestamp":1787148940,"startTime":"0","endTime":"0","summary":"2026年8月19日，恒瑞医药在上海证券交易所网站披露《2026年A股员工持股计划管理办法》，并同步刊发港交所海外监管公告，明确本次员工持股计划的核心安排如下：。单一持有人对应股份数量不超过公司总股本的1%，全部有效员工持股计划累计持股规模不超过公司总股本的10%。恒瑞医药表示，本计划旨在建立公司、股东与员工的利益共享机制，提升员工凝聚力及公司竞争力，促进企业长期可持续发展。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hrs.com.cn","stockEarnings":[{"period":"1week","weight":-0.0196},{"period":"1month","weight":-0.0443},{"period":"3month","weight":-0.1194},{"period":"6month","weight":-0.2077},{"period":"1year","weight":-0.302},{"period":"ytd","weight":-0.2261}],"compareEarnings":[{"period":"1week","weight":0.0022},{"period":"1month","weight":0.014},{"period":"3month","weight":0.0043},{"period":"6month","weight":-0.0348},{"period":"1year","weight":0.0148},{"period":"ytd","weight":-0.0053}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"江苏恒瑞医药股份有限公司是一家主要从事药品的研发、生产和销售的中国公司。该公司专注于肿瘤领域，覆盖激酶抑制剂、抗体偶联药物（ADC）、肿瘤免疫、激素受体调控、脱氧核糖核酸（DNA）修复及表观遗传、支持治疗等研究领域。该公司的产品包括抗肿瘤、镇痛麻醉和造影剂，应用于自身免疫疾病、代谢性疾病、心血管疾病、感染疾病、呼吸系统疾病、血液疾病、疼痛管理、神经系统疾病、眼科、肾病等领域。该公司主要在国内外市场开展其业务。","exchange":"SEHK","name":"恒瑞医药","nameEN":"HENGRUI PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"恒瑞医药(01276)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供恒瑞医药(01276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"恒瑞医药,01276,恒瑞医药股票,恒瑞医药股票老虎,恒瑞医药股票老虎国际,恒瑞医药行情,恒瑞医药股票行情,恒瑞医药股价,恒瑞医药股市,恒瑞医药股票价格,恒瑞医药股票交易,恒瑞医药股票购买,恒瑞医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"恒瑞医药(01276)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供恒瑞医药(01276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}